The agency approved Novartis' Rydapt for AML patients with FLT3 mutations, who will be identified by Invivoscribe's LeukoStrat CDx.
The two companies are expanding a long-term collaboration to include development and commercialization of assays for the Applied Biosystems 3500Dx system.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.
Originally published Dec. 12.
Invivoscribe and Novartis plan to develop an FDA-approved companion test for the investigational AML drug midostaurin and simultaneously launch the drug/test combination worldwide.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.